Bosutinib is a second-generation BCR-ABL tyrosine kinase inhibitor used for chronic myeloid leukaemia, including cases resistant or intolerant to earlier-generation therapies. Simson Pharma's Bosutinib reference standard and impurities support stability-indicating method development for this targeted oncology agent.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Bosutinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.